Do Wall Street Analysts Like Amgen Stock?

Thousand Oaks, California-headquartered Amgen Inc. (AMGN) discovers, develops, and manufactures innovative medicines aimed at improving the lives of millions. With a market cap of $159.6 billion, Amgen has been a pioneer in the biotechnology industry for over 40 years. Its portfolio includes treatments for cancer, heart disease, osteoporosis, inflammatory diseases, and rare conditions.

While Amgen has lagged behind the broader market over the past 52 weeks, it has significantly outperformed it in 2025. AMGN stock has dropped 11.5% over the past 52 weeks and gained 13.9% in 2025, compared to the S&P 500 Index’s ($SPX) 14.5% gains over the past year and 6.1% returns on a YTD basis.